| 0.653 -0.046 (-6.58%) | 12-07 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.95 | 1-year : | 1.12 |
| Resists | First : | 0.81 | Second : | 0.95 |
| Pivot price | 0.8  |
|||
| Supports | First : | 0.58 | Second : | 0.48 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.82 |
| MA(100) : | 2.15 |
MA(250) : | 5.11 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 30.8 |
| RSI | RSI(14): 33.6 |
|||
| 52-week | High : | 12.3 | Low : | 0.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VCNX ] has closed above bottom band by 20.5%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.73 - 0.73 | 0.73 - 0.73 |
| Low: | 0.64 - 0.65 | 0.65 - 0.65 |
| Close: | 0.68 - 0.69 | 0.69 - 0.7 |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Mon, 04 Dec 2023
Vaccinex says Nasdaq gives co extension to regain compliance with listing rule - Seeking Alpha
Mon, 04 Dec 2023
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule - GlobeNewswire
Thu, 26 Oct 2023
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in ... - Yahoo Finance
Fri, 13 Oct 2023
Should You Accumulate Vaccinex Inc (VCNX) Stock Friday Morning? - InvestorsObserver
Fri, 06 Oct 2023
Should You Sell Vaccinex Inc (VCNX) Stock Friday Morning? - InvestorsObserver
Fri, 06 Oct 2023
Why Is Vaccinex (VCNX) Stock Up 26% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -11 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.249e+007 (%) |
| Held by Institutions | 4.88e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.37e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.99 |
| Profit Margin | 0 % |
| Operating Margin | -29 % |
| Return on Assets (ttm) | 170 % |
| Return on Equity (ttm) | -257.6 % |
| Qtrly Rev. Growth | 797.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -364.54 |
| EBITDA (p.s.) | -1.20175e+007 |
| Qtrly Earnings Growth | -2.288e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.12 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 50440 |
| Forward Dividend | 197960 |
| Dividend Yield | 7320750% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|